ABOS vs BIIB
ABOS: Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients, with Phase 2 results expected in late 2026. BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
Side-by-side fundamentals
| Metric | ABOS | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.21 | $197.74 | |
| Market cap as of 2026-07-23 | $160M | $29.8B | |
| P/E as of 2026-07-23 | n/a | 21.75 | |
| PEG as of 2026-07-23 | n/a | 10.24 | |
| Net margin as of 2026-07-23 | -509.7% | +13.8% | BIIB higher |
| Gross margin as of 2026-07-23 | n/a | +75.5% | |
| Operating margin as of 2026-07-23 | -550.0% | +17.5% | BIIB higher |
| ROE as of 2026-07-23 | -123.1% | +7.5% | BIIB higher |
| ROA as of 2026-07-23 | -79.4% | +4.7% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.35 | 0.34 | BIIB lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +1.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.9% | |
| Beta as of 2026-07-23 | 0.32 | 0.16 | |
| 1-year return as of 2026-07-22 close | +43.9% | +54.7% | BIIB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.